Compare F5 Inc (FFIV) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs TG Therapeutics Inc — how do they compare? F5 Inc trades at $415.62 (market cap $23.44B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: F5 Inc is far larger — about 3.1× TG Therapeutics Inc's market cap, and F5 Inc is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| FFIV | TGTX | |
|---|---|---|
Market Cap | $23.44B | $7.64B |
Sector | Technology | Health |
52-Week High | $431.26 | $59.06 |
52-Week Low | $223.99 | $26.94 |
Enterprise Value | $22.08B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) stock trades at $422.95, up 3.16% on the day, near its 52-week high. The company reported strong Q3 2026 earnings, beating estimates with EPS of $4.73 versus $4.00 expected, driven by 19% product revenue growth. Technical indicators show a bullish trend with support at $411 and resistance at $425. Fundamentals remain solid with revenue growth to $3.09B in 2025 and net income margin of 21.95%.
Outlook is positive given raised revenue guidance and robust cybersecurity demand, but valuation multiples like P/E of 32.98 suggest premium pricing. Risks include competitive pressures and execution challenges in sustaining high growth. Analyst consensus is Moderate Buy with a $430.43 price target, indicating modest upside potential from current levels.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
